Long noncoding RNA PART1 restrains aggressive gastric cancer through the epigenetic silencing of PDGFB via the PLZF-mediated recruitment of EZH2
- 8 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 39 (42), 6513-6528
- https://doi.org/10.1038/s41388-020-01442-5
Abstract
Current reports refer to the role of long noncoding RNA (lncRNA) prostate androgen-regulated transcript 1 (PART1) as a tumor suppressor in some types of cancer but as an oncogene in other kinds of cancer. In gastric cancer, it had been reported to be downregulated. However, the clinical significance and underlying mechanism of PART1 function in gastric cancer remains undefined. Here, seven differential expression levels of noncoding RNAs (DE-lncRNAs) were screened from gastric cancer through a probe reannotation of a human exon array. PART1 was selected for further study because of its high fold change number. In our cohort, PART1 was identified as a significant downregulated lncRNA in gastric cancer tissues by qPCR and in situ hybridization (ISH), and its low expression was significantly correlated with postoperative metastasis and short overall survival time after surgery. Through the results of gain-of-function experiments, PART1 was confirmed as a tumor suppressor that can decrease not only cell viability, migration, and invasion in vitro but also tumorigenesis and tumor metastasis in vivo. Mechanistically, RNA pull-down and RNA-binding protein immunoprecipitation (RIP) showed that PART1 interacts with androgen receptor (AR), and then, promyelocytic leukemia zinc finger (PLZF) is upregulated in an androgen-independent manner. In a chain reaction, chromatin immunoprecipitation (ChIP) assay additionally illustrated that PLZF upregulation increased the enrichment of EZH2 and H3K27 trimethylation in the platelet-derived growth factor (PDGFB) promotor, thereby inhibition of PDGFB and the subsequent PDGFRβ/PI3K/Akt signaling pathway. Based on these findings, we showed PART1 plays a tumor suppressor role by promoting PLZF expression followed by recruitment of EZH2 to mediate epigenetic PDGFB silencing and downstream PI3K/Akt inhibition, suggesting that PART1 has a key role in restraining the aggressive ability of GC cells and providing a novel perspective on lncRNAs in GC progression.This publication has 57 references indexed in Scilit:
- lincRNAs: Genomics, Evolution, and MechanismsCell, 2013
- Clinicopathological significance of platelet-derived growth factor B, platelet-derived growth factor recpertor-β, and E-cadherin expression in gastric carcinomaContemporary Oncology, 2013
- Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptorInternational Journal of Oncology, 2012
- Up‐regulated long non‐coding RNA H19 contributes to proliferation of gastric cancer cellsThe FEBS Journal, 2012
- Activation of PI3K/AKT and MAPK Pathway through a PDGFRβ-Dependent Feedback Loop Is Involved in Rapamycin Resistance in Hepatocellular CarcinomaPLOS ONE, 2012
- Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progressionJournal of Hepatology, 2012
- Expression of platelet‐derived growth factor (PDGF)‐B and PDGF‐receptor β is associated with lymphatic metastasis in human gastric carcinomaCancer Science, 2010
- Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Identification and characterization of PLZF as a prostatic androgen‐responsive geneThe Prostate, 2003
- Structural Alterations of Chromosome 5 in Twelve Human Prostate Cancer Cell LinesCancer Genetics and Cytogenetics, 1998